@article{JGO5008,
author = {Andrew S. Kennedy and David S. Ball and Steven J. Cohen and Michael Cohn and Douglas M. Coldwell and Alain Drooz and Eduardo Ehrenwald and Samir Kanani and Charles W. Nutting and Fred M. Moeslein and Samuel G. Putnam III and Steven C. Rose and Michael A. Savin and Sabine Schirm and Navesh K. Sharma and Eric A. Wang},
title = {Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases},
journal = {Journal of Gastrointestinal Oncology},
volume = {6},
number = {6},
year = {2015},
keywords = {},
abstract = {Background: To assess response and the impact of imaging artifacts following radioembolization with yttrium-90-labeled resin microspheres (90Y-RE) based on the findings from a central independent review of patients with liver-dominant metastatic colorectal cancer (mCRC).
Methods: Patients with mCRC who received 90Y-RE (SIR-Spheres®; Sirtex Medical, Sydney, Australia) at nine US institutions between July 2002 and December 2011 were included in the analysis. Tumor response was assessed at baseline and 3 months using either the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 or 1.1. For each lesion, known artifacts affecting the interpretation of response (peri-tumoral edema and necrosis) were documented. Survivals (Kaplan-Meier analyses) were compared in responders [partial response (PR)] and non-responders [stable (SD) or progressive disease (PD)].
Results: Overall, 195 patients (mean age 62 years) received 90Y-RE after a median of 2 (range, 1-6) lines of prior chemotherapy. Using RECIST 1.0 and RECIST 1.1, 7.6% and 6.9% of patients were partial responders, 47.3% and 48.1% had SD, and 55.0% and 55.0% PD, respectively. RECIST 1.0 and RECIST 1.1 showed excellent agreement \{Kappa =0.915 [95% confidence interval (CI): 0.856-0.975]\}. Peri-tumoral edema was documented in 32.8%, necrosis in 48.1% and both in 57.3% of cases (using RECIST 1.0). Although baseline characteristics were similar in responders and non-responders (P>0.05), responders survived significantly longer in an analysis according to RECIST 1.0: PR median (95% CI) 25.2 (range, 9.2-49.4) months vs. SD 15.8 (range, 9.3-21.1) months vs. PD 7.1 (range, 6.0-9.5) months (P},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/5008}
}